Meda AB Has Settled the U.S. Astelin Patent Litigation with Cobalt

STOCKHOLM, Sweden--(BUSINESS WIRE)--Regulatory News: Meda (STO:MEDAA), through its wholly owned U.S. subsidiary, Meda Pharmaceuticals Inc., has entered into a settlement agreement with Cobalt Pharmaceuticals Inc. (hereafter Cobalt) that resolves the U.S. patent litigation between the companies regarding Cobalt’s proposed generic version of Astelin.